骨质疏松症的治疗：未满足的需求与新出现的解决方案
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions.
作者信息
Langdahl Bente Lomholt, Andersen Jane Dahl
机构信息
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
出版信息
J Bone Metab. 2018 Aug;25(3):133-140. doi: 10.11005/jbm.2018.25.3.133. Epub 2018 Aug 31.
Abstract
Efficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non-vertebral fractures by 20%, only one anabolic option is available in most parts of the world-the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. In addition, identification and treatment of patients with high and imminent fracture risk following a recent fracture and long-term adherence to treatment are 2 other very prominent challenges to the management of osteoporosis. The current review will focus on emerging osteoporosis treatments and optimized use of the existing treatments that may help overcome the currently unmet needs in the management of osteoporosis.
摘要
虽然有有效的疗法可用于治疗骨质疏松症，但仍存在未满足的需求。抗吸收疗法仅能在一定程度上增加骨矿物质密度，并将非椎体骨折的风险降低20%，在世界大部分地区只有一种促合成代谢的选择——其效果会随着时间的推移而趋于平稳，而且针对吸收和形成的联合治疗的证据有限。此外，识别和治疗近期骨折后具有高骨折风险和即将发生骨折风险的患者以及长期坚持治疗是骨质疏松症管理的另外两个非常突出的挑战。本综述将重点关注新兴的骨质疏松症治疗方法以及现有治疗方法的优化使用，这些可能有助于克服目前骨质疏松症管理中未满足的需求。
相似文献
1
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions.骨质疏松症的治疗：未满足的需求与新出现的解决方案
J Bone Metab. 2018 Aug;25(3):133-140. doi: 10.11005/jbm.2018.25.3.133. Epub 2018 Aug 31.
2
New horizons in osteoporosis therapies.骨质疏松症治疗的新视野。
Curr Opin Pharmacol. 2016 Jun;28:38-42. doi: 10.1016/j.coph.2016.02.012. Epub 2016 Mar 15.
3
Osteoanabolic Agents for Osteoporosis.用于治疗骨质疏松症的骨合成代谢药物。
J Endocr Soc. 2018 Jul 9;2(8):922-932. doi: 10.1210/js.2018-00118. eCollection 2018 Aug 1.
4
New therapeutic targets for osteoporosis.骨质疏松症的新治疗靶点。
Maturitas. 2019 Feb;120:1-6. doi: 10.1016/j.maturitas.2018.11.010. Epub 2018 Nov 16.
5
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.绝经后骨质疏松症女性中骨合成代谢治疗的疗效比较：一项随机对照试验的系统评价和网络荟萃分析。
Maturitas. 2019 Nov;129:12-22. doi: 10.1016/j.maturitas.2019.08.003. Epub 2019 Aug 10.
6
Recent advances in the management of osteoporosis.骨质疏松症管理的最新进展
F1000Res. 2017 May 5;6:625. doi: 10.12688/f1000research.10682.1. eCollection 2017.
7
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.阿巴洛肽与安慰剂对绝经后骨质疏松症妇女新发椎体骨折的影响：一项随机临床试验。
JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.
8
Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?用于治疗骨质疏松症的合成代谢药物：它们在治疗中可能处于什么地位？
Treat Endocrinol. 2006;5(6):347-58. doi: 10.2165/00024677-200605060-00003.
9
Management of postmenopausal osteoporosis and the prevention of fractures.绝经后骨质疏松症的管理及骨折预防
Panminerva Med. 2014 Jun;56(2):115-31. Epub 2014 Jun 19.
10
[The Importance of teriparatide in the treatment of osteoporosis].[特立帕肽在骨质疏松症治疗中的重要性]
Clin Calcium. 2016 Jun;26(6):905-13.
引用本文的文献
1
Single-Cell Integration of BMD GWAS Results Prioritize Candidate Genes Influencing Age-Related Bone Loss.骨髓密度全基因组关联研究结果的单细胞整合确定了影响年龄相关性骨质流失的候选基因。
JBMR Plus. 2023 Jul 7;7(10):e10795. doi: 10.1002/jbm4.10795. eCollection 2023 Oct.
2
Identification and validation of ferroptosis key genes in bone mesenchymal stromal cells of primary osteoporosis based on bioinformatics analysis.基于生物信息学分析的原发性骨质疏松症骨髓间充质干细胞铁死亡关键基因的鉴定和验证。
Front Endocrinol (Lausanne). 2022 Aug 25;13:980867. doi: 10.3389/fendo.2022.980867. eCollection 2022.
3
A Traditional Chinese Medicine Plant Extract Prevents Alcohol-Induced Osteopenia.一种中药植物提取物可预防酒精性骨质减少。
Front Pharmacol. 2021 Dec 15;12:754088. doi: 10.3389/fphar.2021.754088. eCollection 2021.
4
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.地舒单抗治疗骨质疏松症：10 年后：叙事性综述。
Adv Ther. 2022 Jan;39(1):58-74. doi: 10.1007/s12325-021-01936-y. Epub 2021 Nov 11.
5
Elevation of transaminases associated with teriparatide treatment: a case report.与特立帕肽治疗相关的转氨酶升高：一例报告。
Eur J Hosp Pharm. 2022 Sep;29(5):290-293. doi: 10.1136/ejhpharm-2020-002293. Epub 2020 Nov 16.
6
Therapeutic Potential of Tauroursodeoxycholic Acid for the Treatment of Osteoporosis.牛磺熊去氧胆酸治疗骨质疏松症的潜力。
Int J Mol Sci. 2020 Jun 16;21(12):4274. doi: 10.3390/ijms21124274.
7
Thyroid Hormone Diseases and Osteoporosis.甲状腺激素疾病与骨质疏松症
J Clin Med. 2020 Apr 6;9(4):1034. doi: 10.3390/jcm9041034.
8
Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.抑制素配体：一种用于治疗癌症、骨质疏松症、炎症、心脏和神经疾病的新兴武器。
Cell Mol Life Sci. 2020 Sep;77(18):3525-3546. doi: 10.1007/s00018-020-03475-1. Epub 2020 Feb 15.
9
[Prolonged continuous infusion of teriparatide promotes bone metabolism in normal but not in castrated mice].[持续长时间输注特立帕肽可促进正常小鼠而非去势小鼠的骨代谢]
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Sep 30;39(9):1045-1051. doi: 10.12122/j.issn.1673-4254.2019.09.07.
10
[Diagnostics and treatment of osteoporosis in patients over 65 years old : Current status and future perspectives].65岁以上骨质疏松症患者的诊断与治疗：现状与未来展望
Z Gerontol Geriatr. 2019 Aug;52(5):421-427. doi: 10.1007/s00391-019-01548-w. Epub 2019 May 13.
本文引用的文献
1
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.罗莫佐单抗治疗 24 个月后序贯地舒单抗或安慰剂治疗 12 个月对骨密度低的绝经后妇女的影响：一项随机、双盲、2 期、平行组研究。
J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.
2
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.特立帕肽和利塞膦酸钠对绝经后严重骨质疏松妇女新发骨折的影响（VERO）：一项多中心、双盲、双模拟、随机对照试验。
Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9.
3
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
4
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.罗莫佐单抗（硬骨素单克隆抗体）与特立帕肽在口服双膦酸盐治疗后绝经后骨质疏松症女性中的比较：一项随机、开放标签、3 期临床试验。
Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.
5
Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.绝经后低骨量妇女中，罗莫佐单抗在脊柱和臀部力量方面的增益大于特立帕肽。
J Bone Miner Res. 2017 Sep;32(9):1956-1962. doi: 10.1002/jbmr.3176. Epub 2017 Jun 26.
6
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.骨建模与重塑：作为骨质疏松症治疗靶点的潜力。
Ther Adv Musculoskelet Dis. 2016 Dec;8(6):225-235. doi: 10.1177/1759720X16670154. Epub 2016 Oct 5.
7
Imminent fracture risk.即将发生的骨折风险。
Osteoporos Int. 2017 Jun;28(6):1765-1769. doi: 10.1007/s00198-017-3976-5. Epub 2017 Feb 24.
8
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.皮下注射阿巴洛肽治疗18个月后，对绝经后骨质疏松症女性使用阿仑膦酸钠治疗6个月：ACTIVExtend试验结果
Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009.
9
Imminent risk of fracture after fracture.骨折后即将发生的骨折风险。
Osteoporos Int. 2017 Mar;28(3):775-780. doi: 10.1007/s00198-016-3868-0. Epub 2016 Dec 27.
10
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.罗莫佐单抗治疗绝经后骨质疏松症妇女。
N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18.
Zotero 插件